If you would like to be considered for a clinical trial you will require a referral from your current treating team. Visit the Joining a Clinical Trial page for referral information. For more information on Hodgkin lymphoma and aggressive non-Hodgkin lymphoma clinical trials, get in contact with our Haem B team This email address is being protected from spambots. You need JavaScript enabled to view it..
Open and Recruiting Clinical Trials
INT2104-101 / INVISE
A Two-Part Open Label Phase 1 Multicentre Study Evaluating the Safety of INT2104 Infusions in Female and Male Participants Aged 18 Years of Age and Older with Refractory/Relapsing B-cell Malignancies
Trial IDNCT06539338Cancer typeB-cell lymphomasStatusOpen and recruitingPhasePhase Two: A phase two clinical trial follows a phase one, in a large group of patients with selected cancer types. The aim of a phase two is to find out if the new treatment is effective in these cancer typesWho can participateClinical trials can have restrictive criteria of who can and can’t participate, talk to your doctor if you are interested in this clinical trial.For full inclusion / exclusion criteria refer to the Australian Trials Registry.
D9960C00001 / TITANium
A Modular Phase I/II Open-label Dose Escalation and Dose Expansion Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Efficacy of AZD5492, a T Cell-engaging Antibody Targeting CD20 in Subjects With Relapsed or Refractory B-Cell Malignancies
Trial IDNCT06542250Cancer typeB-cell lymphomasStatusOpen and recruitingPhasePhase one / two: A phase one / two clinical trial combines a phase one and two. The phase one tests new treatments sometimes for the first time in humans, usually in a small group of patients. The phase two-part tests the new treatment in a larger group of patients with selected cancer types. The aim of a phase one / two is to find the best dose of the new treatment and see if it works against the cancerWho can participateClinical trials can have restrictive criteria of who can and can’t participate, talk to your doctor if you are interested in this clinical trial.For full inclusion / exclusion criteria refer to the Australian Trials Registry.
NHL38 / Epcor-Sandwich
A phase II multicentre, single arm, open-label trial of epcoritamab-containing combination salvage therapy followed by autologous stem cell transplantation and epcoritamab consolidation in patients with first relapse of large B-cell lymphoma
Trial IDACTRN12623000620628Cancer typeLarge B-cell lymphomaStatusOpen and recruitingPhasePhase Two: A phase two clinical trial follows a phase one, in a large group of patients with selected cancer types. The aim of a phase two is to find out if the new treatment is effective in these cancer typesWho can participateClinical trials can have restrictive criteria of who can and can’t participate, talk to your doctor if you are interested in this clinical trial.For full inclusion / exclusion criteria refer to the Australian New Zealand Clinical Trials Registry.
22/012 / EpLCART
A Phase II Open-Label, Multi-Centre Study of Minimal Residual Disease-Directed Consolidation With Epcoritamab or Epcoritamab-Lenalidomide-Rituximab Post Anti-CD19 CAR TCell Therapy for Large B-Cell Lymphoma
Trial IDNCT06414148Cancer typeLarge B-cell lymphomaStatusOpen and recruitingPhasePhase Two: A phase two clinical trial follows a phase one, in a large group of patients with selected cancer types. The aim of a phase two is to find out if the new treatment is effective in these cancer typesWho can participateClinical trials can have restrictive criteria of who can and can’t participate, talk to your doctor if you are interested in this clinical trial.For full inclusion / exclusion criteria refer to the Australian Cancer Clinical Trial Registry.
GCT3017-01
A Phase 1/2a, Open-Label, Dose Escalation Trial of GEN3017 With Expansion Cohorts in Relapsed or Refractory CD30+ Classical Hodgkin Lymphoma and CD30+ Non-Hodgkin Lymphoma
Trial ID
NCT06018129
Cancer type
CD30+ T-cell lymphoma (not primary cutaneous)
Status
Open and recruiting (Hodgkin lymphoma recruitment on hold)
Phase
Phase one / two: A phase one / two clinical trial combines a phase one and two. The phase one tests new treatments sometimes for the first time in humans, usually in a small group of patients. The phase two-part tests the new treatment in a larger group of patients with selected cancer types. The aim of a phase one / two is to find the best dose of the new treatment and see if it works against the cancer
Who can participate
Clinical trials can have restrictive criteria of who can and can’t participate, talk to your doctor if you are interested in this clinical trial.
For full inclusion / exclusion criteria refer to ClinicalTrials.gov.
EPCORE CLL-1
A Phase 1b/2, Open-Label, Safety and Efficacy Study of Epcoritamab (GEN3013; DuoBody®-CD3xCD20) in Relapsed/Refractory Chronic Lymphocytic Leukemia and Richter's Syndrome
Trial ID
NCT04623541
Cancer type
Richter’s syndrome and chronic lymphocytic leukaemia
Status
Open and recruiting
Phase
Phase one / two: A phase one / two clinical trial combines a phase one and two. The phase one tests new treatments sometimes for the first time in humans, usually in a small group of patients. The phase two-part tests the new treatment in a larger group of patients with selected cancer types. The aim of a phase one / two is to find the best dose of the new treatment and see if it works against the cancer
Who can participate
Clinical trials can have restrictive criteria of who can and can’t participate, talk to your doctor if you are interested in this clinical trial.
For full inclusion / exclusion criteria refer to the Australian Cancer Clinical Trial Registry.
SkyGLO
A Phase III, Multicenter, Randomized, Open-Label Study Comparing the Efficacy and Safety of Glofitamab (RO7082859) in Combination With Polatuzumab Vedotin Plus Rituximab, Cyclophosphamide, Doxorubicin, and Prednisone (Pola-R-CHP) Versus Pola-R-CHP in Previously Untreated Patients With Large B-Cell Lymphoma
Trial ID
NCT06047080
Cancer type
Large B-cell lymphoma
Status
Open and recruiting
Phase
Phase three: A phase three clinical trial follows a phase two, in a larger group of patients with specific cancer types. The aim of a phase three is to compare the new treatment to existing treatments available for that cancer type
Who can participate
Clinical trials can have restrictive criteria of who can and can’t participate, talk to your doctor if you are interested in this clinical trial.
For full inclusion / exclusion criteria refer to ClinicalTrials.gov.
NHL35 / ALLG-PACIFIC
An Australasian Leukaemia and Lymphoma Group open label phase II study of the effect of of R-CHOP in combination with pembrolizumab in patients with newly diagnosed primary mediastinal B Cell Lymphoma (PMBL)
Trial ID
ACTRN12621001529831
Cancer type
Primary mediastinal B-cell lymphoma
Status
Open and recruiting
Phase
Phase Two: A phase two clinical trial follows a phase one, in a large group of patients with selected cancer types. The aim of a phase two is to find out if the new treatment is effective in these cancer types
Who can participate
Clinical trials can have restrictive criteria of who can and can’t participate, talk to your doctor if you are interested in this clinical trial.
For full inclusion / exclusion criteria refer to the Australian Cancer Clinical Trial Registry.
ZUMA-23
An Adaptive Phase 3, Randomized, Open-Label, Multicenter Study to Compare the Efficacy and Safety of Axicabtagene Ciloleucel Versus Standard of Care Therapy as First-Line Therapy in Subjects With High-Risk Large B-Cell Lymphoma
Trial ID
NCT05605899
Cancer type
Large B-cell lymphoma
Status
Open and recruiting
Phase
Phase three: A phase three clinical trial follows a phase two, in a larger group of patients with specific cancer types. The aim of a phase three is to compare the new treatment to existing treatments available for that cancer type
Who can participate
Clinical trials can have restrictive criteria of who can and can’t participate, talk to your doctor if you are interested in this clinical trial.
For full inclusion / exclusion criteria refer to the Australian Cancer Clinical Trial Registry.
GoldiLox
An Open-label, Single-arm, Phase 2 Trial of GlOfitamab anD pIrtobrutinib (LOXo-305) in Patients With Mantle Cell Lymphoma and Prior Exposure to a BTK Inhibitor
Trial ID
NCT05833763
Cancer type
Mantle cell lymphoma
Status
Recruitment on hold
Phase
Phase Two: A phase two clinical trial follows a phase one, in a large group of patients with selected cancer types. The aim of a phase two is to find out if the new treatment is effective in these cancer types
Who can participate
Clinical trials can have restrictive criteria of who can and can’t participate, talk to your doctor if you are interested in this clinical trial.
For full inclusion / exclusion criteria refer to ClinicalTrials.gov.
NP30179
A Multicenter, Open-Label, Phase I/II Study to Evaluate the Safety, Efficacy, Tolerability and Pharmacokinetics of Escalating Doses of Glofitamab (RO7082859) as a Single Agent and in Combination With Obinutuzumab Administered After a Fixed, Single Dose Pre-Treatment of Obinutuzumab (Gazyva®/Gazyvaro™) in Patients With Relapsed/Refractory B-Cell Non-Hodgkin's Lymphoma
Trial ID
NCT03075696
Cancer type
Mantel cell only
Status
Open and recruiting
Phase
Phase one / two: A phase one / two clinical trial combines a phase one and two. The phase one tests new treatments sometimes for the first time in humans, usually in a small group of patients. The phase two-part tests the new treatment in a larger group of patients with selected cancer types. The aim of a phase one / two is to find the best dose of the new treatment and see if it works against the cancer
Who can participate
Clinical trials can have restrictive criteria of who can and can’t participate, talk to your doctor if you are interested in this clinical trial.
For full inclusion / exclusion criteria refer to the Australian Cancer Clinical Trial Registry.
BP41072
An Open-Label, Phase I Study to Evaluate the Safety, Pharmacokinetics and Preliminary Antitumor Activity of RO7227166 (a CD19 Targeted 4-1BB Ligand) in Combination With Obinutuzumab and in Combination With Glofitamab Following a Pre-Treatment Dose of Obinutuzumab Administered in Participants With Relapsed/Refractory B-Cell Non-Hodgkin's Lymphoma
Trial ID
NCT04077723
Cancer type
B-cell non-Hodgkin lymphoma
Status
Recruitment on hold
Phase
Phase one: A phase one clinical trial tests new treatments sometimes for the first time in humans, usually in a small group of patients. The aim of a phase one clinical trial is to test the safety of the new treatment and find the best dose to give patients
Who can participate
Clinical trials can have restrictive criteria of who can and can’t participate, talk to your doctor if you are interested in this clinical trial.
For full inclusion / exclusion criteria refer to the Australian Cancer Clinical Trial Registry.
ARDENT
A Phase 1 Study Evaluating SC291, a Hypoimmune, Allogeneic CD19-directed CAR T Cell Therapy, in Relapsed and/or Refractory B-cell Malignancies
Trial ID
NCT05878184
Cancer type
B-cell malignancies (chronic lymphocytic leukaemia, follicular lymphoma, diffuse large B-cell lymphoma, marginal zone lymphoma and mantel cell lymphoma)
Status
Open and recruiting
Phase
Phase one: A phase one clinical trial tests new treatments sometimes for the first time in humans, usually in a small group of patients. The aim of a phase one clinical trial is to test the safety of the new treatment and find the best dose to give patients
Who can participate
Clinical trials can have restrictive criteria of who can and can’t participate, talk to your doctor if you are interested in this clinical trial.
For full inclusion / exclusion criteria refer to ClinicalTrials.gov.
NKARTA
A Phase 1 Study of NKX019, a CD19 Chimeric Antigen Receptor Natural Killer (CAR NK) Cell Therapy, in Subjects With B-cell Malignancies
Trial ID
NCT05020678
Cancer type
B-cell malignancies (only diffuse large B-cell lymphoma)
Status
Open and recruiting
Phase
Phase one: A phase one clinical trial tests new treatments sometimes for the first time in humans, usually in a small group of patients. The aim of a phase one clinical trial is to test the safety of the new treatment and find the best dose to give patients
Who can participate
Clinical trials can have restrictive criteria of who can and can’t participate, talk to your doctor if you are interested in this clinical trial.
For full inclusion / exclusion criteria refer to the Australian Cancer Clinical Trial Registry.
BGB-11417-101
A Phase 1a/1b Open-Label Dose Escalation and Expansion Study of Bcl-2 Inhibitor BGB-11417 in Patients With Mature B-Cell Malignancies
Trial ID
NCT04277637
Cancer type
B-cell malignancies (chronic lymphocytic leukaemia and mantel cell lymphoma only)
Status
Open and recruiting
Phase
Phase one: A phase one clinical trial tests new treatments sometimes for the first time in humans, usually in a small group of patients. The aim of a phase one clinical trial is to test the safety of the new treatment and find the best dose to give patients
Who can participate
Clinical trials can have restrictive criteria of who can and can’t participate, talk to your doctor if you are interested in this clinical trial.
For full inclusion / exclusion criteria refer to the Australian Cancer Clinical Trial Registry.
If you don’t find what you are looking for or would like a center closer to home that may also provide similar clinical trials, refer to the Victorian Cancer Trials Link or Australian Clinical Trials Registry.
